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In several  organisms,  the  ﬁrst barrier  against  microbial  infections  consists  of  antimicrobial  peptides
(AMPs)  which  are  molecules  that  act  as components  of the  innate  immune  system.  Recent  studies  have
demonstrated  that  AMPs  can  perform  various  functions  in different  tissues  or  physiological  conditions.
In  this  view,  this  study  was  carried  out  in  order  to  evaluate  the  multifunctional  activity  in vivo  of  an
alanine-rich  peptide,  known  as  Pa-MAP,  derived  from  the  polar  ﬁsh  Pleuronectes  americanus.  Pa-MAP  was
evaluated  in  intraperitoneally  infected  mice  with  a sub-lethal  concentration  of  Escherichia  coli  at  standard
concentrations  of  1 and  5 mg kg−1.  At  both  concentrations,  Pa-MAPs  exhibited  an  ability  to  prevent  E. coli
infection  and  increase  mice  survival,  similar  to the  result  observed  in mice  treated  with  ampicillin  at
2  mg  kg−1. In  addition,  mice  were  monitored  for weight  loss.  The  results  showed  that  mice  treated  with
Pa-MAPs  at  1 mg  kg−1 gained  0.8%  of body  weight  during  the  72  h  of experiment.  The  same  was observed
−1with  Pa-MAP  at  5 mg  kg , which  had  a gain  of  0.5%  in  body  weight  during  the  treatment.  Mice  treated
with  ampicillin  at  2  mg  kg−1 show  a signiﬁcant  weight  loss  of  5.6%  of  body  weight.  The  untreated  group
exhibited  a 5.5%  loss  of  body  weight.  The  immunomodulatory  effects  were  also evaluated  by the quan-
tiﬁcation  of IL-10,  IL-12,  TNF-,  IFN- and nitric  oxide  cytokines  in serum,  but no  immunomodulatory
activity  was  observed.  Data  presented  here  suggest  that  Pa-MAP  should  be used as a novel  antibiotic
against  infection  control.
. Introduction
Bacterial infection control in hospitalized patients is an enor-
ous challenge due to numerous contamination sources including
nvasive procedures and devices such as mechanical ventilators
10], ultrasound probes [50] and catheters [58]. Aiming to con-
rol such microorganisms, permanent surveillance protocols are
dopted in hospitals informing about preventive strategies to
educe infection [9,52]. According to the World Health Organization
WHO), 8.7% of hospitalized patients of 55 hospitals in 14 countries
n 4 WHO  regions (Europe, Eastern Mediterranean, South-East Asia
nd Western Paciﬁc) and 1.4 million people world-wide suffer from
osocomial infections [53]. Moreover, nosocomial infections have
 direct impact on country costs due to increases in length of hos-
italization, number of physician visits and deaths [15,33].Enterobacteriacea is one of the most prevalent bacterial families
n nosocomial infections mainly represented by Pseudomonas aeu-
uginosa, Klebsiella pneumoniae and Escherichia coli [10,28]. E. coli
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is a facultative anaerobe able to colonize the human large intestine
and can be divided in virulent and avirulent strains. Virulence
factors that differentiate these strains are commonly acquired on
mobile genetic elements by horizontal gene transference. Further-
more, these virulence factors confer upon E. coli strains the ability to
resist to human host defenses [20,39]. E. coli strains are attributed
to cause nosocomial infections and a wide number of human
diseases, such as sepsis, meningitis, and diarrhea [30,35,36,47].
Otherwise, the application of novel antimicrobials seems to be
an alternative for infectious disease treatment including the devel-
opment of antimicrobial peptides (AMPs) [7,23]. AMPs consist of
peptides from 12 to 100 amino acid residues length, which exert
activity against Gram-positive and -negative bacteria, fungi and
viruses through multiple mechanisms [12,26,43]. These peptides
can be isolated from various organisms such as plants [48], insects
[45], amphibians [57], ﬁshes [1] and mammals [18]. Despite their
different origins, AMPs may show some common properties includ-
ing cationic surfaces and amphipathic structures [49]. Furthermore,
some peptides also show promiscuity as they attach to differ-
ent targets such as membranes, cell walls, cytosolic proteins and
Open access under the Elsevier OA license.nucleic acids [7,27,49]. This property could lead to multifunction-
ality derived from a single protein molecule. This process could
also occur due to a speciﬁc stimulus, such as pH or protein con-
centrations. This property is commonly found in plant and animal
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cillin at 2 mg  kg dissolved in 100 L of PBS was utilized as the
positive control. Moreover, an uninfected control was also per-
formed. All mice were housed with constant water and food in an
air-ﬁltered environment maintained at 20 ± 2 ◦C during 72 h and
Table 1
Experimental groups distribution.
Experimental groups (n = 5) E. coli infection Treatments
1 – Infected Yes Ampicillin 2 mg kg−1
2 – Infected and untreated Yes No
3 – Non infected No NoL.D. Teixeira et al. / Pe
efense peptides, in which a wide number of different functions
ust be generated by several structural homologs with identical
tructures [16]. Moreover, cationic AMPs conformation seems to
nteract with anionic microorganism membranes by electrostatic
nteractions in a ﬁrst step. AMPs inset into membrane bilayers and
ggregate, forming pores and leading to an efﬂux of intracellular
ons [40,64].
Additionally, some studies have shown the relation between
esistance to certain infectious diseases and AMPs secretion.
ipriano et al. [8] showed that AMPs secreted in ﬁsh exter-
al mucus may  confer resistance to Aeromonas salmonicida in
almonids. Likewise, in Teleostei marine polar ﬁsh, some pep-
ides are commonly secreted into the blood and tissues depending
n sub-zero temperature [13,31]. These peptides are known as
ntifreeze peptides (AFP), and the type I AFP family is commonly
ound in winter ﬂounder (Pleuronectes americanus), named HPLC-
 and HPLC-8 [18]. Comparing AMPs and AFPs, similar structural
nd physical–chemical properties have been found, such as the
ydrophobic ratio, hydrophobic moment and speciﬁc amino acid
omposition [61]. Migliolo et al. [34] studied a synthetic peptide
amed Pa-MAP, a derivate of the HPLC-8 peptide [25]. Addition-
lly, Pa-MAP primary sequence was selected from the AFP HPLC-8
roduced by the polar ﬁsh P. americanus with length (decreased
rom 37 residues to 26) and residue modiﬁcations, such as lysine
 and 18 substituted by alanine, valine 2 and 13 by treonine, and
lutamic acid 11 by alanine. The ﬁrst amino acid residue in HPLC-
 is aspartic acid, also substituted by histidine [34]. Surprisingly,
a-MAP is devoid of arginine and lysine cationic residues, which
eems to be important for antimicrobial activity [19,41]. Indeed,
he peptide has mostly hydrophobic amino acid residues suggest-
ng that that Pa-MAP antimicrobial activity could be attributed
ostly to hydrophobic interaction. Furthermore, it shows the abil-
ty of inhibiting the HSV virus, the development of mycellar fungi
. mentagrophytes and T. rubrum, and deleterious activity against
. coli, besides cytotoxic effects in tumor cells. Moreover, Pa-MAP
id not show any cytotoxic effects against human red blood cells,
nabling this peptide for in vivo assays. An additional activity was
he antitumoral effects against Caco-2 (human epithelial colorectal
denocarcinoma cells), HCT-116 (human colorectal carcinoma cell
ines) and MCF-7 (human breast cancer cells) [34].
One of the main challenges of AMP  utilization has been related
o peptide stability in such models. Several studies have demon-
trated that the activity of AMPs in vitro was not the same as in vivo
odels, and these controversial results may  be attributed to certain
roteases present in serum [22]. Another cause of in vivo inactivity
s the high polar property of some AMPs, resulting in a reduction
n membrane crossing or in an irregular distribution into mam-
alian cells, losing activity against intracellular microorganisms
59]. Moreover, as revised by Brinch et al. [3], in vivo AMP  activity
ay also be impeded by poor drug distribution and AMP  degrada-
ion by increased metabolism inside the cell. AMPs also can induce
he immune system to produce anti-AMP antibodies [2], reducing
heir effectiveness
In  this view, this study evaluated the in vivo antimicrobial activ-
ty of the synthetic multifunctional peptide Pa-MAP. Mice infected
ith E. coli strains were used as experimental models. Moreover,
he serum was obtained and cytokines were evaluated in order to
etermine a possible immunomodulatory effect.
. Materials and methods.1.  Peptide synthesis and mass spectrometry analyses
The Pa-MAP peptide was synthesized by China Peptides
Shanghai, China) based on two 11-residue repeating segments 42 (2013) 144–148 145
from  HPLC-8 with the following sequence: H-His-Thr-Ala-Ser-Asp-
Ala-Ala-Ala-Ala-Ala-Ala-Leu-Thr-Ala-Ala-Asn-Ala-Ala-Ala-Ala-
Ala-Ala-Ala-Ser-Met-Ala-NH2, with the stepwise solid-phase
method using the N-9-ﬂuorenylmethyloxycarbonyl (Fmoc) strat-
egy with a Rink amine resin (0.52 mmol  g−1), and puriﬁed by
reversed-phase high-performance liquid chromatography (HPLC)
with purity degree >95% [6,34]. Pa-MAP molecular mass was
determined using matrix assisted laser desorption/ionization
time  of ﬂight mass spectrometry (MALDI-ToF MS/MS) analysis
on UltraFlex III, Bruker Daltonics, Billerica, MA.  Puriﬁed peptides
were dissolved in a minimum volume of water that was mixed
with an -cyano-4-hydroxycinnamic acid saturated matrix solu-
tion (1:3, v:v), spotted onto a MALDI target plate and dried at
room temperature for 5 min. The -cyano-4-hydroxycinnamic
acid  matrix solution was  prepared at 50 mM in H2O:ACN:TFA
(50:50:0.3, v:v:v). Peptide monoisotopic mass was obtained in
the reﬂector mode with external calibration using the Peptide
Calibration Standard II for mass spectrometry (up to 4000 Da mass
range, Bruker Daltonics, Billerica, MA).
2.2. Bacterial strains and growth conditions
Escherichia coli (ATCC 8739) strains were cultivated in solid
Muller–Hinton medium. An isolated colony was transferred to 5 mL
of liquid Luria–Bertani (LB) medium and grown in a rotating drum
at 37 ◦C with aeration during 24 h. Posteriorly, 100 L of this pre
inoculum was transferred to 4.9 mL  of LB medium and grown at the
same conditions for 2 h. The absorbance was  evaluated to identify
the late log phase, when the OD at 600 nm was  1.0, corresponding
a concentration of 1 × 108 UFC mL−1 (5 × 108 UFC at ﬁnal volume).
These cells were centrifuged for 6 min  at 1200 rpm and the sedi-
ment was resuspended in 5 mL  of phosphate buffered saline (PBS)
and equalized to a concentration of 1 × 106 UFC at ﬁnal volume for
virulence and immunomodulatory assays [63].
2.3. Escherichia coli in vivo bioassays
In vivo experiments were performed with 6–10 weeks old
female BALB/c mice from University of Campinas (Campinas/SP).
Mice were housed and used in accordance with guidelines
established by the Ethical Committee of Animal Use of Univer-
sity of Brasília (Brasilia/DF), registered under protocol number
UnBDOC:83931/2011, and all efforts were made to minimize ani-
mal  suffering. Mice were divided into 5 groups of 5 animals each
(Table 1). As described above, groups were infected via intraperi-
toneal (IP) injection with E. coli suspension equalized and diluted
in cold PBS to a sub lethal concentration of 1 × 105 UFC  (50 L in
each animal) [54]. Treatments of infected mice were performed
with Pa-MAP at 1 and 5 mg  kg−1, both dissolved in 100 L of PBS,
respectively. PBS was utilized as the negative control, and ampi-
−14 – Infected and treated group 1 Yes Pa-MAP 1 mg  kg−1
5 – Infected and treated group 2 Yes Pa-MAP 5 mg  kg−1
Groups 1, 2, 4 and 5 were infected with E. coli at 1 ×105 UFC sublethal concentration.
Drug  treatments were injected 24 and 48 h after infection.
146 L.D. Teixeira et al. / Peptides 42 (2013) 144–148
Fig. 1. (A) MALDI-TOF mass spectrometry analysis of Pa-MAP monoisotropic mass [M+H+] = 2212.86. (B) After E. coli sub lethal infection, mice were treated with ampicillin
at 2mg  kg−1 ( ), Pa-MAP at 1 ( ) and 5 mg  kg−1 ( ) at 24 h and 48 h. At 24 h, 20% of mice of infected and untreated group ( ) died and another 20% had died at
48  h. ( ) represent the Untreated group. (a) represent Logrank test with p < 0.05, Chi square = 11.67, compared to negative control. (C and D) Weight loss was evaluated at
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ained weight until the end of the experiment, as well as mice that were uninfected 
urther treated as described above (Table 1). Treatments occurred
4 h and 48 h after infection. Moreover, all mice were weighed at
he beginning and at the end of the experiment.
.4. Cytokines evaluation
Mice  were anesthetized by xilazine and ketamine at 10 mg  kg−1
nd 50 mg  kg−1, respectively, after 72 h. Blood collection was per-
ormed by decapitation and serum obtained by centrifugation
nd stored at −20 ◦C. The cytokines interleukin-10 (IL-10), IL-12,
nterferon gamma  (IFN-), tumor necrosis factor alpha (TNF-),
nd nitric oxide (NO) were measured in serum by enzyme-linked
mmunosorbent assays (ELISA) using ELISA kit (Peprotech) accord-
ng to the manufacturer’s instructions.
.5. Statistical Analysis
The  statistical signiﬁcance of the experimental results was
etermined by one-way Student’s t-test or one-way analysis of
ariance (ANOVA) followed by Dunnett’s test. Values of P < 0.05
ere considered statistically signiﬁcant. Graphpad Prism version
.0 was used for all statistical analyses.
. Results
.1. Mass spectrometry analysis
MALDI-ToF evaluation showed an ion with an m/z  of 2212.86,
orresponding to the calculated value for the peptide sequence,
bove 95% in purity. All further bioassays were performed using
uriﬁed Pa-MAP (Fig. 1A)..2. Antimicrobial activities
In  order to conﬁrm the in vitro protective effects of Pa-MAP
gainst E. coli, in vivo antibacterial activity was evaluated by ad group and mice treated with ampicillin at 2 mg kg−1. Mice treated with Pa-MAP
treated. (D) Difference of weight from each group at 72 h after procedures. P > 0.05.
sub-lethal  E. coli mice IP infection. Two concentrations of Pa-MAP
(1 mg  kg−1 and 5 mg  kg−1) treatment were tested. Ampicillin at
2 mg  kg−1 was used as a positive control. During the ﬁrst 24 h after
infection, the infected and untreated group decreased 20%, fur-
ther decreasing to 60% 48 h after infection. In contrast, all mice
treated with Pa-MAP in both concentrations survived at the end of
experiment. The same pattern was  observed in mice treated with
ampicillin (Fig. 1B).
Mice  weights were further evaluated in the beginning and at the
end of experiment. Infected and untreated mice lost 5.5% of their
body weight after 72 h of experiment. In contrast, mice treated with
Pa-MAP at 1 mg  kg−1 gained 0.8% of their body weight, similar to
Pa-MAP at 5 mg  kg−1, which gained 0.5% of their body weight dur-
ing the same period. Non-infected mice gained slightly more body
weight (2.7%) compared to the Pa-MAP treatment groups. Infected
mice treated with ampicillin at 2 mg  kg−1 also had lost weight,
equivalent to 5.6% of their initial body weight (Fig. 1C and D).
3.3.  Immunomodulatory activity
Some cytokines were evaluated in attempt to identify an
immunomodulatory effect of Pa-MAP in the mice immunologic sys-
tem. This evaluation of immunomodulatory activity in vivo was
investigated by quantiﬁcation of IL-10, IL-12, TNF- and NO in
serum. Pa-MAP used as treatment was evaluated at 1 mg  kg−1, cor-
responding to a concentration of twice the minimum inhibitory
concentration (MIC) of 512 g mL−1 [34], and 5 mg kg−1, corre-
sponding 10 times the MIC  encountered in early study with
Pa-MAP. Ampicillin at 2 mg  kg−1 was used as a positive control.
These concentrations of Pa-MAP were unable to modify IL-10
release when compared to the non-infected and untreated mice
group. Similar data were observed for IL-12 and TNF- production
in all treatments groups (Supplementary Fig. 1).
See Supp Figure S1 as supplementary ﬁle. Supplementary
material  related to this article found, in the online version, at
http://dx.doi.org/10.1016/j.peptides.2013.02.001.
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. Discussion
Antimicrobial resistance mechanisms developed by bacteria
s a serious worldwide threat to public health, particularly for
mmunocompromised patients and those under immunosuppres-
ion therapy, e.g. patients after organ transplant [29]. Moreover,
nfections caused by antibiotic-resistant microorganisms have con-
ributed to increases in patient mortality, especially for those
hose treatment with currently available drugs has become less
fﬁcient [14]. Due to these facts, peptides with antimicrobial activi-
ies have become extremely attractive for microorganisms control,
ainly due their low toxicity effects into mammalian cells [24].
n our study, an alanine-rich peptide designed from a polar ﬁsh,
. americanus, with two  repeat antifreeze motifs and clear in vitro
eleterious activity against E. coli, with identical puriﬁcation degree
see Fig. 1A) previously reported by Migliolo et al. [34] was  evalu-
ted in vivo.
Some  peptides were designed to develop a multifunctional
roduct, able to eliminate microbes and increase the immune
esponse, involving systematic variations in the structure of a
ase molecule, i.e. cationic charge, hydrophobicity and hydropho-
ic moment [21]. Moreover, some cationic peptides are known to
e able to induce some immunomodulatory effect [37,62]. Some
tudies demonstrated that only a fraction of the peptide was pre-
ented to the immune system, and these peptides should be able
o overcome some “bottlenecks” and only those with speciﬁc char-
cteristics would be able to induce the immune system [32,46].
evertheless, Pa-MAP seems to be unable to interact with immune
ystem cells to induce cytokine production. Data presented here
hows that Pa-MAP neither signiﬁcantly stimulates nor inhibits
ome cytokine production, despite of others could be modiﬁed by
he presence of peptide. This result is similar to the Fritsche et al.
tudies [17]. In their studies, it was demonstrated that a short,
roline-rich antimicrobial peptide has direct antibacterial action
n vivo, but was unable to stimulate cytokine production.
Despite the absence of immunomodulatory activity, data
eported here shows strong evidence that the peptide Pa-MAP
ould be useful for pharmaceutical design once it shows the abil-
ty to perform E. coli inhibition in vivo. Pa-MAP demonstrated in
ivo activity against E. coli at low concentrations when compared
o other antimicrobial peptides. Schaal et al. [51] demonstrated
imilar effect with rhesus -defensin (RTD), a macrocyclic antimi-
robial peptide expressed in leukocytes of Old World monkeys.
his RTD peptide was administrated at a single subcutaneous dose
t 5 mg  kg−1 in mice previously intraperitoneally infected with
. coli and resulted in an increase in mice survival. Vingsbo et al.
60] demonstrated that the novel synthetic polymyxin derivatives
AB737 and NAB739 are as effective as polymyxin B, an effective
ntibiotic against Gram-negative bacterial infections, in effectively
reating E. coli peritoneal infection in mice at 1, 2 and 4 mg  kg−1.
n another study, a non-natural AMP  named M33  (with 9 amino
cid residues long) showed the ability at 12.5 and 25.0 mg  kg−1 to
rotect 100% of mice infected with lethal doses of E. coli and P.
eruginosa. Lower concentrations were unable to protect mice [42].
Although antimicrobial activity, the mechanism of action has
een unclear until now. Some researchers have suggested that
MPs can cause bacterial membrane disruption, leading to intracel-
ular leakage and later microorganism death [4]. In addition, AMPs
an interact with immune cells and increase immune response in
he face of injury or inﬂammation, modulating the innate immune
esponse, for example, through chemotactic activity, stimulation
f cytokine release, neutralization of LPS-induced septic effects,
ound healing and tissue repair [11]. Nevertheless, Pa-MAP did
ot exhibit the ability to stimulate cytokine release from immune
ells as previously described, suggesting that direct microorganism
ontrol could be related to the Pa-MAP mechanism of action. 42 (2013) 144–148 147
One of the most documented effects of E. coli infection is pro-
gressive weight loss, mainly due to water loss during infection
[44]. This symptom is also caused by heat-labile toxin (LT) and
heat-stable toxin (ST) presented in enterotoxigenic E. coli infec-
tion [55]. In the current study, 5.5% of mice body weight loss was
observed in the infected and untreated group. A study developed
in murine model, mice infected with non-pathogenic and entero-
hemorrhagic E. coli (NPEC and EHEC) demonstrated a clear weight
loss of about 6% [5]. Furthermore, mice treated with ampicillin at
2 mg  kg−1 also showed 5.6% weight loss, demonstrating that ampi-
cillin can eliminate bacterial infection, but did not exhibit ability to
inhibit weight loss. In contrast, Pa-MAP exhibited protective effects
against E. coli and body weight loss in both concentrations, preven-
ting this pathological effect. Similar data was  observed in a study
with the AMP  IB-367, a protegrin peptide, evaluated to prevent oral
mucositis in hamsters. In this study, animals treated with IB-367 at
0.12–2.0 mg  mL−1 showed body weight gain in comparison with
mice treated with placebo, and became signiﬁcantly greater during
the passing days [38]. Soni et al. [56] evaluated in vivo the efﬁcacy
of two  combined antibiotics, ceftriaxone and vancomycin, against
E. coli intra-abdominally infected mice. Infected mice showed sig-
niﬁcant weight loss during infection and became normalized after
vancomycin and ceftriaxone treatment.
5. Conclusions
Due to increasing number of cases of multi-resistant bacterial
disease against a variety of antimicrobial drugs, antimicrobial pep-
tides have a great and considerable potential to become the new
generation of bioactive products. Here, a peptide with an antimicro-
bial novel effect in vivo was conﬁrmed but any immunomodulatory
activity was observed indicting that action mechanism is only
related to a direct antimicrobial activity. This peptide demonstrated
a protective effect against E. coli at lower concentrations in compar-
ison to other antimicrobial peptides and synthetic pharmacological
antibiotics [42,60]. Moreover, weight loss in mice was prevented
during treatment with Pa-MAP, in contrast with other treatments,
i.e. ampicillin and other AMPs. In the future, Pa-MAP could be used
in the development of a novel biopharmaceutical against microor-
ganisms.
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